Study #2023-1045
A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280 in patients with unresectable locally advanced or metastatic cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
TAK-280
Description
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Unresectable Locally Advanced or Metastatic Cancer
Study phase:
Physician name:
George Blumenschein
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-737-0154
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.